Avalo Therapeutics (NASDAQ:AVTX) CFO Christopher Ryan Sullivan Sells 8,458 Shares

Avalo Therapeutics, Inc. (NASDAQ:AVTX) CFO Christopher Ryan Sullivan sold 8,458 shares of Avalo Therapeutics stock in a transaction that occurred on Wednesday, April 29th. The shares were sold at an average price of $13.09, for a total transaction of $110,715.22. Following the completion of the transaction, the chief financial officer owned 8,880 shares of the company’s stock, valued at $116,239.20. This trade represents a 48.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christopher Ryan Sullivan also recently made the following trade(s):

• On Thursday, April 30th, Christopher Ryan Sullivan sold 8,457 shares of Avalo Therapeutics stock. The shares were sold at an average price of $13.23, for a total transaction of $111,886.11.
• On Thursday, April 2nd, Christopher Ryan Sullivan sold 7,980 shares of Avalo Therapeutics stock. The shares were sold at an average price of $17.15, for a total transaction of $136,857.00.
• On Wednesday, April 1st, Christopher Ryan Sullivan sold 7,979 shares of Avalo Therapeutics stock. The shares were sold at an average price of $16.77, for a total transaction of $133,807.83.

Avalo Therapeutics Trading Up 2.3%

NASDAQ:AVTX opened at $13.71 on Friday. Avalo Therapeutics, Inc. has a 1 year low of $3.39 and a 1 year high of $20.72. The firm has a 50 day moving average of $15.29 and a 200-day moving average of $16.19. The stock has a market capitalization of $366.19 million, a P/E ratio of -2.39 and a beta of 0.78.

Avalo Therapeutics (NASDAQ:AVTX) last issued its quarterly earnings results on Monday, March 23rd. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.54) by $1.17. The company had revenue of $0.06 million during the quarter, compared to analyst estimates of ($0.21) million. As a group, analysts forecast that Avalo Therapeutics, Inc. will post -4.04 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

AVTX has been the topic of a number of research reports. Citizens Jmp began coverage on shares of Avalo Therapeutics in a research report on Monday, April 6th. They set an “outperform” rating and a $52.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Avalo Therapeutics in a research report on Wednesday, April 8th. Guggenheim began coverage on shares of Avalo Therapeutics in a research report on Monday, February 2nd. They set a “buy” rating and a $50.00 target price for the company. Wolfe Research began coverage on shares of Avalo Therapeutics in a research report on Thursday, April 9th. They set an “outperform” rating and a $48.00 target price for the company. Finally, BTIG Research reiterated a “buy” rating and set a $40.00 target price on shares of Avalo Therapeutics in a research report on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.83.

Hedge Funds Weigh In On Avalo Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. PFS Partners LLC grew its holdings in shares of Avalo Therapeutics by 100.0% in the 4th quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock valued at $36,000 after buying an additional 1,000 shares during the period. BIT Capital GmbH acquired a new position in shares of Avalo Therapeutics in the 3rd quarter valued at $25,000. Geode Capital Management LLC grew its holdings in shares of Avalo Therapeutics by 2.5% in the 2nd quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock valued at $552,000 after buying an additional 2,648 shares during the period. Dimensional Fund Advisors LP acquired a new position in Avalo Therapeutics in the 3rd quarter worth $143,000. Finally, Boothbay Fund Management LLC acquired a new position in Avalo Therapeutics in the 2nd quarter worth $56,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.